Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

The emergence of COVID-19 has led to a pandemic that has caused millions of cases of
disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir …

The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Although efficacious vaccines have significantly reduced the morbidity and mortality of
COVID-19, there remains an unmet medical need for treatment options, which monoclonal …

Summary SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19, making
them a focus of vaccine design. A safety concern regarding SARS-CoV-2 antibodies is …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the
main target for neutralizing antibodies. These antibodies can be elicited through …

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-
19, little is known about their mechanism (s) of action or effective dosing windows. We report …